Navigation Links
Ventas Declares Regular Quarterly Dividend of $0.475 Per Share
Date:9/5/2007

LOUISVILLE, Ky., Sept. 5 /PRNewswire-FirstCall/ -- Ventas, Inc. (NYSE: VTR) ("Ventas" or the "Company") said today that its Board of Directors declared a regular quarterly dividend of $0.475 per share, payable in cash on September 28, 2007, to stockholders of record on September 17, 2007. The dividend is the third quarterly installment of the Company's $1.90 per share 2007 annual dividend.

Ventas, Inc. is a leading healthcare real estate investment trust. Its diverse portfolio of properties located in 43 states and two Canadian provinces includes seniors housing communities, skilled nursing facilities, hospitals and medical office and other properties. More information about Ventas can be found on its website at http://www.ventasreit.com.

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding Ventas, Inc.'s ("Ventas" or the "Company") and its subsidiaries' expected future financial position, results of operations, cash flows, funds from operations, dividends and dividend plans, financing plans, business strategy, budgets, projected costs, capital expenditures, competitive positions, acquisitions, investment opportunities, merger integration, growth opportunities, expected lease income, continued qualification as a real estate investment trust ("REIT"), plans and objectives of management for future operations and statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will" and other similar expressions are forward-looking statements. Such forward-looking statements are inherently uncertain, and security holders must recognize that actual results may differ from the Company's expectations. The Company does not undertake a duty to update such forward-
'/>"/>

SOURCE Ventas, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. WHO Declares Vietnam First Country to Control SARS
2. Prime Minister Declares War on AIDS
3. WHO declares Tuberculosis – ‘An Emergency’ in Afrca
4. Iranian Government Declares Holiday Due To Pollution
5. Florida State University declares a breathtaking study which might solve the Hepatitis C Virus maze and find a cure!
6. Fao Declares Humans Spread Avian Influenza Virus
7. Myanmar Declares Herself As A Country Free of Bird flu
8. Ramadoss Declares India Yaws Free
9. China Declares War on Unsafe Foods for Soldiers
10. Startling Expose – Physicians Often Have No Regular Source Of Health Car
11. Regular exercise prevents hip fractures
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2008)...ug. 29 /PRNewswire-FirstCall/ -- Landauer, Inc. (N...ors declared a regular,quarterly cash dividend of ...008. The dividend will be paid on October 3, 2008,... About Landauer, Landauer is the leading provide... and environmental radiation exposure. For more th...
(Date:8/29/2008)...fic obligation reduced from $250 to $19 million, ...oston Scientific,Corporation (NYSE: BSX ) today a... Texas found two patents of Medtronic, Inc. (NYSE:...ng the prosecution of the patents,before the Unite... previously found that certain Boston Scientific b...
(Date:8/29/2008)... Dr. Milton Owens and the Coastal Center for O...ia to provide protection for cash paying patients ...ic community is benefiting. , .... Milton Owens and the Coastal Center for Obesity ...rovide protection for cash paying patients in the ...
(Date:8/29/2008)... Trusted life science software provider allows...ngage via GSA. , Reston, ...erging software engineering firm dedicated to the...ral Services Administration (GSA) Contract. The GS...h the ability to conveniently engage 5AM Solutions...
Breaking Medicine News(10 mins):Health News:Court Rejects Two Medtronic Patents 2Health News:Court Rejects Two Medtronic Patents 3Health News:Coastal Center for Obesity Offers Hispanics Weight Loss Surgery with a Warranty 2Health News:Federal and State Agencies Have Easier Access to 5AM Solutions' Award-Winning Software Services 2
...occus Aureus) is a bacteria resistant to certain a...ients who suffer //from weakened immune systems, e...own to spread because of poor hygiene. Countries l...ay, where MRSA has been relatively low and stable ...
...an children with AIDS, five Bulgarian Nurses and a...sion //in the Court of Appellations in Tripoli. ...pital aids made the outbreak possible since all th...ive results. But the Libyan authorities refused th...
...ng various opinions on the issue of doctors being ...atients //without fear of a ban. In its new draf... careful and remind them that the relationship wou...appropriate. In a move that nullifies the past p...
...rsity School of Medicine and colleagues finds it’s...lt medical procedures //about the dizzy feel of na...trongly affect how they respond to adversity – bot...d lead author Max E. Levine, Ph.D. ‘Being prepared...
Other Medicine News:Health News:Super-bug MRSA Getting Fitter And Out of Control 2Health News:Precautious Measure Help Tolerate Nausea In Patients 2Health News:Precautious Measure Help Tolerate Nausea In Patients 3
(Date:8/27/2008)...Spraying Set for Tonight in Parts of Bucks, Delawa..., Pa., Aug. 27 /PRNewswire-USNewswire/ -- After en...ial treatments, the Department of,Environmental Pr... protect,the public against the mosquito-borne Wes... administered between 8 p.m. and,midnight in porti...
(Date:8/27/2008)...rd Winning Research Team Makes Crucial Breakthroug...of Parkinson,s Disease, CHICAGO, Aug. 27 /PRNewsw...on today announced that scientists at The Universi...in the battle to slow or prevent the onset,of a ve...., The researchers have genetically produced the ...
(Date:8/27/2008)... - First Phase 3 data, from BLISS-52 trial, expec...l, BLISS-76, expected by fall 2009 -, ROCKVILLE, ...e,Sciences, Inc. (Nasdaq: HGSI ) today announced ...BLISS-76, the second of two pivotal Phase 3,random...) in patients with,active systemic lupus erythemat...
(Date:8/26/2008)... INDIANAPOLIS, Aug. 26 /- Semafore Ph... Seventh International Congress on Targeted,Therap...nal antiangiogenic,activity of vascular-targeted P...h VEGF and Bv8 signaling., PI3K is part of a very...has been shown to play a major role in cancer. Stu...
Breaking Medicine Technology:DEP to Complete Aerial Mosquito Treatments to Stem West Nile Virus in Southeastern Counties 2DEP to Complete Aerial Mosquito Treatments to Stem West Nile Virus in Southeastern Counties 3The University of Nottingham in the British Midlands Announces Breakthrough in Parkinson's Disease Research 2Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 2Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 3Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 4Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 5Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 6SF1126, Semafore's PI3 Kinase Inhibitor, Found to Block Angiogenic Signaling From Both VEGF and Bv8 in Multiple Cell Lines 2SF1126, Semafore's PI3 Kinase Inhibitor, Found to Block Angiogenic Signaling From Both VEGF and Bv8 in Multiple Cell Lines 3Surprise U S Supreme Court Decision Helps Michigan Citizens 13313 1mtvU 26 The Jed Foundation Go Beyond March Madness Spring Break 26 5th Anniversary of Iraq War Dedicating March Programming to College Students Me 13310 1mtvU 26 The Jed Foundation Go Beyond March Madness Spring Break 26 5th Anniversary of Iraq War Dedicating March Programming to College Students Me 13310 2mtvU 26 The Jed Foundation Go Beyond March Madness Spring Break 26 5th Anniversary of Iraq War Dedicating March Programming to College Students Me 13310 3mtvU 26 The Jed Foundation Go Beyond March Madness Spring Break 26 5th Anniversary of Iraq War Dedicating March Programming to College Students Me 13310 4mtvU 26 The Jed Foundation Go Beyond March Madness Spring Break 26 5th Anniversary of Iraq War Dedicating March Programming to College Students Me 13310 5mtvU 26 The Jed Foundation Go Beyond March Madness Spring Break 26 5th Anniversary of Iraq War Dedicating March Programming to College Students Me 13310 6RealSelf com Denies Lifestyle Lifts Trademark Claims and Files Countersuit 13307 1RealSelf com Denies Lifestyle Lifts Trademark Claims and Files Countersuit 13307 2Beauty com Partners With Fashion Designer Jenni Kayne 13304 1Beauty com Partners With Fashion Designer Jenni Kayne 13304 2Beauty com Partners With Fashion Designer Jenni Kayne 13304 3Beauty com Partners With Fashion Designer Jenni Kayne 13304 4
...led Findings Presented at 2007 APA Meeting Also Sh...axine Succinate, COLLEGEVILLE, Pa., May 21, 2007 /...e pooled analyses - one examining the,effect of de...,other on painful symptoms associated with major d...pooled analysis that examined the,effect of desven...
...t-hoc analysis shows nearly nine out of ten patien...at the end of 12 months, WASHINGTON, D.C., May 22,...III, open-label 12-14 month extension study (303),...gy (BSG) meeting,in Glasgow, Scotland in March 200...lerated in mild to moderate UC,patients. Today, se...
Other Medicine Technology:Pooled Studies Showed Desvenlafaxine Succinate Significantly,Improved Painful Symptoms and Anxious Symptoms Associated with,Major Depressive Disorder in Adults, Compared With Placebo 2Pooled Studies Showed Desvenlafaxine Succinate Significantly,Improved Painful Symptoms and Anxious Symptoms Associated with,Major Depressive Disorder in Adults, Compared With Placebo 3Pooled Studies Showed Desvenlafaxine Succinate Significantly,Improved Painful Symptoms and Anxious Symptoms Associated with,Major Depressive Disorder in Adults, Compared With Placebo 4Pooled Studies Showed Desvenlafaxine Succinate Significantly,Improved Painful Symptoms and Anxious Symptoms Associated with,Major Depressive Disorder in Adults, Compared With Placebo 5Pooled Studies Showed Desvenlafaxine Succinate Significantly,Improved Painful Symptoms and Anxious Symptoms Associated with,Major Depressive Disorder in Adults, Compared With Placebo 6Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 2Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 3Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 4Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 5Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 6Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 7Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 8
...gnostics is a leading provider of immunofluorescen... that includes kits for autoimmune diseases, infec...onjugates and components. Our Impact IFA Test Syst...it sizes to choose from. Kit components include su...
...gnostics is a leading provider of immunofluorescen... that includes kits for autoimmune diseases, infec...onjugates and components. Our Impact IFA Test Syst...it sizes to choose from. Kit components include su...
...gnostics is a leading provider of immunofluorescen... that includes kits for autoimmune diseases, infec...onjugates and components. Our Impact IFA Test Syst...it sizes to choose from. Kit components include su...
...ELISA products make us a leader in this field. Wit...into the busy laboratory, our Infectious Disease E...n-to-run consistency. Our Infectious Disease ELISA...e range of serological assays including ToRCH, EBV...
Medicine Products: